News from Kitos |
![]() In a recent perspective article published on Nature Reviews Drug Discovery (link), various members of the European Cell-Based Assays Interest Group summarized limitations of traditional cell-based disease models and discuss how patient-derived cultures, induced pluripotent stem cell (iPSC) technology and 3D co-cultures, complemented by single-cell imaging, microfluidics and gene editing technologies, could improve clinical significance of preclinical drug testing. In this view, limitations of standard cell-line screens and in vivo xenografts contributed to the failure of many drug candidates that did not show clinical efficacy:
0 Comments
|